Departments of Pharmacology, Rouen University Hospital, Rouen, France.
Hypertension. 2012 Dec;60(6):1415-21. doi: 10.1161/HYPERTENSIONAHA.112.201087. Epub 2012 Oct 22.
In young healthy subjects, epoxyeicosatrienoic acids synthesized by endothelial cytochrome P450 epoxygenases maintain basal conduit artery diameter during altered NO availability. Whether this compensatory mechanism is effective during essential hypertension is unknown. Radial artery diameter, blood flow, and mean wall shear stress were determined in 14 nontreated essential hypertensive patients and 14 normotensive control subjects during 8 minutes of brachial infusion for inhibitors of cytochrome P450 epoxygenases (fluconazole, 0.4 µmol/min) and NO synthase (N(G)-monomethyl-L-arginine, 8 µmol/min) alone and in combination. In controls, the radial artery diameter was reduced by fluconazole (-0.034 ± 0.012 mm) and N(G)-monomethyl-L-arginine (-0.037 ± 0.010 mm) and to a larger extent by their combination (-0.137 ± 0.011 mm), demonstrating a synergic effect. In contrast, the radial diameter in hypertensive patients was not affected by fluconazole (0.010 ± 0.014 mm) but was reduced by N(G)-monomethyl-L-arginine (-0.091 ± 0.008 mm) to a larger extent than in controls. In parallel, N(G)-monomethyl-L-arginine decreased local plasma nitrite to a lesser extent in hypertensive patients (-14 ± 5 nmol/L) than in controls (-50 ± 10 nmol/L). Moreover, the addition of fluconazole to N(G)-monomethyl-L-arginine did not further decrease radial diameter in patients (-0.086 ± 0.011 mm). Accordingly, fluconazole significantly decreased local epoxyeicosatrienoic acid plasma level in controls (-2.0 ± 0.6 ng/mL) but not in patients (-0.9 ± 0.4 ng/mL). Inhibitors effects on blood flow and endothelium-independent dilatation to sodium nitroprusside were similar between groups. These results show that, in contrast to normotensive subjects, epoxyeicosatrienoic acids did not contribute to the regulation of basal conduit artery diameter and did not compensate for altered NO availability to maintain this diameter in essential hypertensive patients.
在年轻健康的受试者中,内皮细胞细胞色素 P450 加氧酶合成的环氧二十碳三烯酸在一氧化氮可用性改变时维持基础导引导管直径。在原发性高血压中,这种代偿机制是否有效尚不清楚。在 14 名未经治疗的原发性高血压患者和 14 名正常血压对照者中,通过肱动脉输注细胞色素 P450 加氧酶抑制剂(氟康唑,0.4μmol/min)和一氧化氮合酶抑制剂(N(G)-单甲基-L-精氨酸,8μmol/min),单独和联合,测定 8 分钟内的桡动脉直径、血流和平均壁切应力。在对照组中,氟康唑(-0.034±0.012mm)和 N(G)-单甲基-L-精氨酸(-0.037±0.010mm)使桡动脉直径减小,并且联合使用时减小的程度更大(-0.137±0.011mm),表现出协同作用。相比之下,高血压患者的桡动脉直径不受氟康唑的影响(0.010±0.014mm),但 N(G)-单甲基-L-精氨酸的影响更大(-0.091±0.008mm),比对照组更明显。同时,与对照组(-50±10nmol/L)相比,N(G)-单甲基-L-精氨酸使高血压患者局部血浆硝酸盐减少的程度较小(-14±5nmol/L)。此外,氟康唑加 N(G)-单甲基-L-精氨酸的添加并未使患者的桡动脉直径进一步减小(-0.086±0.011mm)。因此,氟康唑显著降低对照组的局部环氧二十碳三烯酸血浆水平(-2.0±0.6ng/ml),但不降低患者的水平(-0.9±0.4ng/ml)。两组之间抑制剂对血流和内皮依赖性扩张至硝普钠的作用相似。这些结果表明,与正常血压受试者相比,环氧二十碳三烯酸不参与基础导引导管直径的调节,也不能代偿一氧化氮可用性的改变以维持原发性高血压患者的这种直径。